Conatus Pharmaceuticals (CNAT) Tops Q4 EPS by 2c

March 7, 2018 4:07 PM

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q4 EPS of ($0.15), $0.02 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $9.49 million.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

Categories

Earnings Guidance